Oneness Biotech Co Ltd Asset Resilience Ratio
Oneness Biotech Co Ltd asset resilience ratio. Oneness Biotech Co Ltd (4743) has an Asset Resilience Ratio of 45.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Oneness Biotech Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oneness Biotech Co Ltd (2009–2025)
Asset resilience ratio of Oneness Biotech Co Ltd from 2009 to 2025. This chart shows how Oneness Biotech Co Ltd's Asset Resilience Ratio has changed over time. See Oneness Biotech Co Ltd (4743) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Oneness Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Oneness Biotech Co Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$5.07 Billion | 45.0% |
| Total Liquid Assets | NT$5.07 Billion | 45.00% |
Asset Resilience Insights
- Very High Liquidity: Oneness Biotech Co Ltd maintains exceptional liquid asset reserves at 45.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oneness Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Oneness Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Oneness Biotech Co Ltd Asset Resilience Ratio by Year (2009–2025)
Oneness Biotech Co Ltd asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Oneness Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.49% | NT$4.16 Billion ≈ $131.21 Million |
NT$11.73 Billion ≈ $369.67 Million |
-8.22pp |
| 2024-12-31 | 43.71% | NT$5.97 Billion ≈ $188.13 Million |
NT$13.66 Billion ≈ $430.35 Million |
-1.59pp |
| 2023-12-31 | 45.30% | NT$6.96 Billion ≈ $219.28 Million |
NT$15.36 Billion ≈ $484.04 Million |
+29.95pp |
| 2022-12-31 | 15.35% | NT$2.39 Billion ≈ $75.35 Million |
NT$15.58 Billion ≈ $490.87 Million |
-32.15pp |
| 2021-12-31 | 47.50% | NT$7.47 Billion ≈ $235.44 Million |
NT$15.73 Billion ≈ $495.61 Million |
-5.14pp |
| 2020-12-31 | 52.65% | NT$8.10 Billion ≈ $255.17 Million |
NT$15.38 Billion ≈ $484.69 Million |
+32.28pp |
| 2019-12-31 | 20.37% | NT$1.42 Billion ≈ $44.79 Million |
NT$6.98 Billion ≈ $219.90 Million |
-0.11pp |
| 2018-12-31 | 20.48% | NT$478.25 Million ≈ $15.07 Million |
NT$2.34 Billion ≈ $73.58 Million |
-15.19pp |
| 2017-12-31 | 35.67% | NT$899.36 Million ≈ $28.33 Million |
NT$2.52 Billion ≈ $79.44 Million |
-15.55pp |
| 2016-12-31 | 51.22% | NT$1.31 Billion ≈ $41.24 Million |
NT$2.56 Billion ≈ $80.52 Million |
+12.26pp |
| 2015-12-31 | 38.95% | NT$1.09 Billion ≈ $34.45 Million |
NT$2.81 Billion ≈ $88.45 Million |
-18.75pp |
| 2014-12-31 | 57.71% | NT$1.16 Billion ≈ $36.62 Million |
NT$2.01 Billion ≈ $63.46 Million |
+7.32pp |
| 2013-12-31 | 50.39% | NT$1.05 Billion ≈ $33.18 Million |
NT$2.09 Billion ≈ $65.84 Million |
+27.30pp |
| 2012-12-31 | 23.09% | NT$329.27 Million ≈ $10.37 Million |
NT$1.43 Billion ≈ $44.93 Million |
+11.10pp |
| 2011-12-31 | 11.99% | NT$166.31 Million ≈ $5.24 Million |
NT$1.39 Billion ≈ $43.71 Million |
+0.33pp |
| 2009-12-31 | 11.66% | NT$129.76 Million ≈ $4.09 Million |
NT$1.11 Billion ≈ $35.07 Million |
-- |
About Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, whic… Read more